Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 2
2005 1
2006 4
2007 13
2008 3
2009 1
2010 4
2011 15
2012 8
2013 8
2014 14
2015 18
2016 12
2017 19
2018 15
2019 16
2020 20
2021 26
2022 41
2023 34
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
The development of small-molecule inhibitors targeting HPK1.
Zhou L, Wang T, Zhang K, Zhang X, Jiang S. Zhou L, et al. Among authors: jiang s. Eur J Med Chem. 2022 Dec 15;244:114819. doi: 10.1016/j.ejmech.2022.114819. Epub 2022 Oct 4. Eur J Med Chem. 2022. PMID: 36209628 Review.
Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M, Wang T, Zhang X, Wu X, Jiang S. Wang M, et al. Among authors: jiang s. Future Med Chem. 2020 May;12(9):813-833. doi: 10.4155/fmc-2019-0334. Epub 2020 Mar 25. Future Med Chem. 2020. PMID: 32208930 Review.
Targeting tropomyosin receptor kinase for cancer therapy.
Miao Q, Ma K, Chen D, Wu X, Jiang S. Miao Q, et al. Among authors: jiang s. Eur J Med Chem. 2019 Aug 1;175:129-148. doi: 10.1016/j.ejmech.2019.04.053. Epub 2019 Apr 30. Eur J Med Chem. 2019. PMID: 31077998 Review.
258 results